Exelixis Inc Increase (Decrease) in Other Receivables
Exelixis Inc (EXEL) reported Increase (Decrease) in Other Receivables of -$2.47 million for the 9-month period ending 2019-09-27, per its 10-Q filed 2019-10-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2019-10-30
- Exelixis Inc increase (decrease) in other receivables for the quarter ending 2019-09-27 was $1.19M.
- Exelixis Inc increase (decrease) in other receivables for the quarter ending 2019-06-28 was $5.08M, a 45.58% decline year-over-year.
- Exelixis Inc increase (decrease) in other receivables for the quarter ending 2019-03-29 was -$8.74M.
- Exelixis Inc increase (decrease) in other receivables for the quarter ending 2018-12-28 was $1.47M.
- Exelixis Inc increase (decrease) in other receivables for fiscal 2018 was $4.41M.
- Exelixis Inc increase (decrease) in other receivables for fiscal 2017 was -$2.46M.
- Exelixis Inc increase (decrease) in other receivables for fiscal 2016 was -$3.36M.
- Exelixis Inc increase (decrease) in other receivables for fiscal 2013 was $1.19M.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2019-09-27 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $6.27M derived: sum of 2 quarters · filed 2019-10-30 | -$2.47M 10-Q · filed 2019-10-30 | -$997.00K derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-06-28 | $5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$3.66M 10-Q · filed 2019-07-31 | -$2.19M derived: sum of 3 quarters · filed 2019-07-31 | -$8.52M derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-03-29 | -$8.74M 10-Q · filed 2019-05-01 | -$7.27M derived: sum of 2 quarters · filed 2019-05-01 | -$13.60M derived: sum of 3 quarters · filed 2019-10-30 | -$4.27M derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-12-28 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$4.86M derived: sum of 2 quarters · filed 2019-10-30 | $4.47M derived: sum of 3 quarters · filed 2019-10-30 | $4.41M 10-K · filed 2019-02-22 |
| 2018-09-28 | -$6.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $3.00M derived: sum of 2 quarters · filed 2019-10-30 | $2.94M 10-Q · filed 2019-10-30 | |
| 2018-06-29 | $9.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $9.27M 10-Q · filed 2019-07-31 | ||
| 2018-03-30 | -$64.00K 10-Q · filed 2019-05-01 | |||
| 2017-12-29 | -$2.46M 10-K · filed 2019-02-22 | |||
| 2016-12-30 | -$3.36M 10-K · filed 2019-02-22 | |||
| 2014-03-31 | $516.00K 10-Q · filed 2014-05-01 | -$714.00K derived: sum of 2 quarters · filed 2014-05-01 | $248.00K derived: sum of 3 quarters · filed 2014-05-01 | $592.00K derived: sum of 4 quarters · filed 2014-05-01 |
| 2013-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$268.00K derived: sum of 2 quarters · filed 2014-02-20 | $76.00K derived: sum of 3 quarters · filed 2014-02-20 | $1.19M 10-K · filed 2014-02-20 |
| 2013-09-30 | $962.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $1.31M derived: sum of 2 quarters · filed 2013-10-30 | $2.42M 10-Q · filed 2013-10-30 | $2.46M derived: sum of 4 quarters · filed 2014-05-01 |
| 2013-06-30 | $344.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $1.46M 10-Q · filed 2013-08-06 | $1.50M derived: sum of 3 quarters · filed 2014-05-01 | $1.93M derived: sum of 4 quarters · filed 2014-05-01 |
| 2013-03-31 | $1.11M 10-Q · filed 2014-05-01 | $1.16M derived: sum of 2 quarters · filed 2014-05-01 | $1.58M derived: sum of 3 quarters · filed 2014-05-01 | $1.95M derived: sum of 4 quarters · filed 2014-05-01 |
| 2012-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $468.00K derived: sum of 2 quarters · filed 2014-02-20 | $832.00K derived: sum of 3 quarters · filed 2014-02-20 | -$27.04M 10-K · filed 2014-02-20 |
| 2012-09-30 | $424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $788.00K derived: sum of 2 quarters · filed 2013-10-30 | -$27.08M 10-Q · filed 2013-10-30 | -$1.55M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $364.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$27.51M 10-Q · filed 2013-08-06 | -$1.97M derived: sum of 3 quarters · filed 2014-02-20 | -$3.68M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | -$27.87M 10-Q · filed 2013-05-07 | -$2.33M derived: sum of 2 quarters · filed 2014-02-20 | -$4.04M derived: sum of 3 quarters · filed 2014-02-20 | -$3.45M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $25.54M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $23.83M derived: sum of 2 quarters · filed 2014-02-20 | $24.42M derived: sum of 3 quarters · filed 2014-02-20 | $24.29M 10-K · filed 2014-02-20 |
| 2011-09-30 | -$1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$1.12M derived: sum of 2 quarters · filed 2012-11-07 | -$1.24M 10-Q · filed 2012-11-07 | -$2.65M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $592.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $467.00K 10-Q · filed 2012-08-02 | -$943.00K derived: sum of 3 quarters · filed 2013-02-21 | $335.00K derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | -$125.00K 10-Q · filed 2012-05-03 | -$1.53M derived: sum of 2 quarters · filed 2013-02-21 | -$257.00K derived: sum of 3 quarters · filed 2013-02-21 | |
| 2010-12-31 | -$1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | -$132.00K derived: sum of 2 quarters · filed 2013-02-21 | -$5.97M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$4.56M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | -$5.84M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $8.51M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |